Benoit spent over 30 years growing healthcare businesses and solving fast growth-related issues as an entrepreneur, investor, advisor, or board member.
He created and led the leading continental European clinical stage CRO in the 90s and has been instrumental in the development of Mapi from 2001, then a few dozen employees’ company, until its sale to Icon with 800 people and revenues north of €100m in 2017.
Benoit has a dual scientific (PharmD Pharmacy 1984; PhD Pharmaceutical Sciences/Biotechnology 1986) and business (Advanced Management Program Harvard Business School 2002) education. His professional background enabled him to gain an in-depth knowledge of all aspects of a healthcare venture stage company and to favor understanding and collaboration between scientists and business persons.
In the investment banking field, he was at Puilaetco (a Belgian brokerage firm since acquired by KBC) head of equity research team between 1998 and 2002, joined Bryan Garnier (a leading M&A boutique and brokerage firm) to create the healthcare practice and then became a senior advisor, healthcare to IMAP, a 400 M&A professionals network until 2017.
He has been instrumental in the emergence of several funds investing in private and public innovative healthcare companies. Several times ranked by Thomson Reuters as a top five healthcare analyst, he also sourced and led the execution of over 40 M&A transactions and financing rounds for biotechnology and medical device, and outsourcing companies.
He joined NEOMED-LABS in 2017 with the assignment to transform a vaccine R&D unit that had been spun-off from GSK in 2015 with 55 people into a global immunology laboratory services player. He led a MBO backed by Ampersand Capital in July 2018, acquired Pacific Biomarkers and PAIRimmune since that date and the company now rebranded as Nexelis has more than tripled its size in 2 years.
With over 30 years of general management and global operations experience, Tim joined the company in March 2019 with a focus on the integration of business operations to ensure efficiency and bring best market practices on board. Tim has worked extensively in laboratory and commercial settings, including Quintiles Transnational and Q2 Solutions, where he served as Global Head for Bioanalytical, Immunoassay, and Absorption, Distribution, Metabolism and Excretion (ADME) laboratories. He was responsible for multiple sites in the US and Europe and was the Head of Central Labs in the Americas with sites in North and South America with over 500 employees. In the COO role, Tim has global responsibility for Laboratory Operations, Project Management, Data Management, Quality Assurance, and Information Technology. He graduated from the University of Massachusetts with a degree in Business Management.
Vahé has 25 years of experience in finance and accounting, with the last 15 years in the Pharma/Vaccine industry, mainly as North American Finance Head for GlaxoSmithKline Vaccines (GSK).
He also worked in the technology industry for private and public companies, for start-up and global structures in the manufacturing and servicing industries. During his career, Vahé was involved in M&A, integrations, IPO, global transactions, but also with operating responsibilities by leading finance teams. In 2015, he was involved in the creation of NEOMED-LABS by leading the project from the GSK side. He joined the company as a CFO in August 2017 where he manages the finance functions and supports the strategic growth of the company. Vahé is a CPA-CMA and holds an MBA from HEC Montreal.
Luc leads the scientific operations at Nexelis to support vaccines and biologics throughout the different phases of clinical trials. Luc is a biochemist by training and holds a PhD degree in Microbiology/Immunology from Laval University.
He is armed with over 20 years of experience in several biotech, CRO, and pharmaceutical companies, with an extensive expertise in ligand-binding and functional assay development, qualification and validation.
Abigail joined the company in February of 2019 and serves as Site Head and Vice President of Project Management and Operations. In her current position, Abigail manages all laboratory, project management and facilities’ operations at Seattle. Abigail received a Bachelor of Science degree in Microbiology from the University of Kansas in Lawrence, Kansas. Additionally, she received her Cytotechnologist and Specialist in Laboratory Safety Certifications through the American Society for Clinical Pathology (ASCP). Abigail brings over 20 years of Life Sciences experience to her role at Nexelis. Abigail worked at Covance Central Laboratories, spending over 11 years in a variety of roles in project management, leadership and operations, leading the launch of the Vaccines and Novel Immunotherapeutics department in 2015. In 2018, Abigail joined Q2 Laboratory Solutions as Associate Clinical Operations Director, managing and enhancing strategic client relationships throughout the lifecycle of each project and portfolio.
In her current position Tonya manages the IT group responsible for network infrastructure and systems administration as well as the data management group that provides trial data to our sponsors at the Seattle site. She is also the Data Protection Officer (DPO).
Tonya receive a Bachelor of Arts degree in Biological Sciences from Western Washington University and a Bachelor of Science degree in Electrical Engineering from the University of Washington. She began her career as a systems engineer in aerospace research at Boeing Aerospace. This has been followed by over 25 years of experience in the health care industry. She joined National Health Laboratories (later to become LabCorp) as Assistant Manager of Information Systems where she was able to bring together her experience with computer systems/software and her background in biological sciences. She later joined Pacific Biomarkers (now Nexelis) as Information Systems Manager and in her tenure with the company she has had various roles in overseeing IT, data and project management. Throughout, her teams’ focus is ensuring the integrity of the data from receipt of samples thru reporting as well as meeting data deliverables on or ahead of schedule.